BridgeBio Pharma Inc at Citi BioPharma Conference (Virtual)- Panel: TTR Amyloidosis Transcript
Hello, and welcome to our panel discussion on TTR amyloidosis. Now I'm really pleased that we kind of have a better group of panelists here today. From Alnylam, we have Eric Green, he's the senior Vice President and General Manager of the TTR program. Next, we have Neil Kumar, CEO of both BridgeBio and its subsidiary, Ionis therapeutics; and from Ionis, we have Brett Monia, CEO.
So first for our listeners, I'd like to point out that each of these companies has a deep pipeline that goes far beyond TTR amyloidosis. On this, certainly worth taking a look at but for today, we'll keep the discussions focused on TTR.
So with that in mind, could each of you give an overview of your TTR programs? Perhaps let's start with Neil.
Yes. Sure. Well, first of all, thanks for being on this panel, Joel, and it's great to see colleagues here all working on the same big unmet need. I'll give a quick overview of what we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
